Nature Clinical Practice Oncology Nature Clinical Practice Oncology provides oncologists with authoritative and timely interpretations of key developments in the field, translating the latest findings into clinical practice. http://www.nature.com/ncponc/current_issue/ Nature Publishing Group en © 2008 Nature Publishing Group Nature Clinical Practice Oncology 1743-4254 1743-4262 © 2008 Nature Publishing Group permissions@nature.com Nature Clinical Practice Oncology http://www.nature.com/includes/rj_globnavimages/ncponc_logo.gif http://www.nature.com/ncponc/ The era of personalized medicine: back to basics http://dx.doi.org/10.1038/ncponc1253 The era of personalized medicine: back to basics

Nature Clinical Practice Oncology 5, 623 (2008). doi:10.1038/ncponc1253

Authors: Lisa Hutchinson & Vincent T DeVita

]]> The era of personalized medicine: back to basics Lisa Hutchinson Vincent T DeVita doi:10.1038/ncponc1253 Nature Clinical Practice Oncology 5, 623 (2008) Nature Clinical Practice Oncology 5 11 Editorial 623 623 Preoperative chemoradiotherapy improves outcomes in nonresectable rectal cancer http://dx.doi.org/10.1038/ncponc1232 Preoperative chemoradiotherapy improves outcomes in nonresectable rectal cancer

Nature Clinical Practice Oncology 5, 624 (2008). doi:10.1038/ncponc1232

]]> Preoperative chemoradiotherapy improves outcomes in nonresectable rectal cancer doi:10.1038/ncponc1232 Nature Clinical Practice Oncology 5, 624 (2008) Nature Clinical Practice Oncology 5 11 Research Highlights 624 624 PKA overexpression predicts treatment outcome in men with prostate cancer http://dx.doi.org/10.1038/ncponc1233 PKA overexpression predicts treatment outcome in men with prostate cancer

Nature Clinical Practice Oncology 5, 624 (2008). doi:10.1038/ncponc1233

]]> PKA overexpression predicts treatment outcome in men with prostate cancer doi:10.1038/ncponc1233 Nature Clinical Practice Oncology 5, 624 (2008) Nature Clinical Practice Oncology 5 11 Research Highlights 624 624 Fractionated total body irradiation and etoposide confer remission in Ph+ ALL http://dx.doi.org/10.1038/ncponc1234 Fractionated total body irradiation and etoposide confer remission in Ph+ ALL

Nature Clinical Practice Oncology 5, 624 (2008). doi:10.1038/ncponc1234

]]> Fractionated total body irradiation and etoposide confer remission in Ph+ ALL doi:10.1038/ncponc1234 Nature Clinical Practice Oncology 5, 624 (2008) Nature Clinical Practice Oncology 5 11 Research Highlights 624 625 KRAS mutations do not predict response to 5-fluorouracil chemotherapy http://dx.doi.org/10.1038/ncponc1235 KRAS mutations do not predict response to 5-fluorouracil chemotherapy

Nature Clinical Practice Oncology 5, 625 (2008). doi:10.1038/ncponc1235

]]> KRAS mutations do not predict response to 5-fluorouracil chemotherapy doi:10.1038/ncponc1235 Nature Clinical Practice Oncology 5, 625 (2008) Nature Clinical Practice Oncology 5 11 Research Highlights 625 625 Lapatinib therapy for patients with advanced renal cell carcinoma http://dx.doi.org/10.1038/ncponc1220 Lapatinib therapy for patients with advanced renal cell carcinoma

Nature Clinical Practice Oncology 5, 626 (2008). doi:10.1038/ncponc1220

Author: Brian I Rini

]]> Lapatinib therapy for patients with advanced renal cell carcinoma Brian I Rini doi:10.1038/ncponc1220 Nature Clinical Practice Oncology 5, 626 (2008) 2008-09-02 Nature Clinical Practice Oncology 2008-09-02 5 11 Practice Point 626 627 Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance http://dx.doi.org/10.1038/ncponc1221 Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance

Nature Clinical Practice Oncology 5, 628 (2008). doi:10.1038/ncponc1221

Authors: Michael B Sporn & Waun Ki Hong

]]> Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance Michael B Sporn Waun Ki Hong doi:10.1038/ncponc1221 Nature Clinical Practice Oncology 5, 628 (2008) 2008-08-26 Nature Clinical Practice Oncology 2008-08-26 5 11 Practice Point 628 629 Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma http://dx.doi.org/10.1038/ncponc1216 Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma

Nature Clinical Practice Oncology 5, 630 (2008). doi:10.1038/ncponc1216

Authors: Myron Schwartz & Joshua Weintraub

]]> Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma Myron Schwartz Joshua Weintraub doi:10.1038/ncponc1216 Nature Clinical Practice Oncology 5, 630 (2008) 2008-08-19 Nature Clinical Practice Oncology 2008-08-19 5 11 Practice Point 630 631 Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards oncocardiology http://dx.doi.org/10.1038/ncponc1226 The combination of dyspnea, exercise limitation and muscle weakness is known as cancer fatigue syndrome. Dyspnea is an important symptom in patients with cancer and also in patients with chronic heart failure. The authors of this Viewpoint hypothesize that cancer fatigue syndrome represents clinically non-overt heart failure, and postulate that cardiac-like symptoms in cancer develop in a similar manner to symptoms of chronic heart failure. Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards oncocardiology

Nature Clinical Practice Oncology 5, 632 (2008). doi:10.1038/ncponc1226

Authors: Martin Schünemann, Stefan D Anker & Mathias Rauchhaus

]]> Cancer fatigue syndrome reflects clinically non-overt heart failure: an approach towards oncocardiology Martin Schünemann Stefan D Anker Mathias Rauchhaus doi:10.1038/ncponc1226 Nature Clinical Practice Oncology 5, 632 (2008) 2008-09-23 Nature Clinical Practice Oncology 2008-09-23 5 11 Viewpoint 632 633 Response criteria for glioma http://dx.doi.org/10.1038/ncponc1204 The current method for assessing response to therapy of glial tumors is based on the Macdonald et al. criteria; however, these criteria are ambiguous in key features such as the appropriate threshold for lesion size and the actual methods for applying the stated criteria. The authors of this Review identify the strengths and shortcomings of the current approach and also discuss technological advances in both drug therapy and imaging that necessitate reassessment of the Macdonald et al. criteria. Response criteria for glioma

Nature Clinical Practice Oncology 5, 634 (2008). doi:10.1038/ncponc1204

Authors: A Gregory Sorensen, Tracy T Batchelor, Patrick Y Wen, Wei-Ting Zhang & Rakesh K Jain

]]> Response criteria for glioma A Gregory Sorensen Tracy T Batchelor Patrick Y Wen Wei-Ting Zhang Rakesh K Jain doi:10.1038/ncponc1204 Nature Clinical Practice Oncology 5, 634 (2008) 2008-08-19 Nature Clinical Practice Oncology 2008-08-19 5 11 Review 634 644 Facts and controversies in the use of trastuzumab in the adjuvant setting http://dx.doi.org/10.1038/ncponc1219 Five adjuvant breast cancer trials have clearly demonstrated the benefit of trastuzumab in reducing the recurrence rate and mortality in patients with aggressive HER2-positive disease. The controversies and challenges relating to the use of trastuzumab in the adjuvant setting, such as the optimal timing and duration, its use with taxanes and radiotherapy, its role in small node-negative tumors and cost-effectiveness are discussed. Facts and controversies in the use of trastuzumab in the adjuvant setting

Nature Clinical Practice Oncology 5, 645 (2008). doi:10.1038/ncponc1219

Authors: Phuong Dinh, Evandro de Azambuja, Fatima Cardoso & Martine J Piccart-Gebhart

]]> Facts and controversies in the use of trastuzumab in the adjuvant setting Phuong Dinh Evandro de Azambuja Fatima Cardoso Martine J Piccart-Gebhart doi:10.1038/ncponc1219 Nature Clinical Practice Oncology 5, 645 (2008) 2008-09-09 Nature Clinical Practice Oncology 2008-09-09 5 11 Review 645 654 Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy http://dx.doi.org/10.1038/ncponc1225 Cardiovascular disease in patients with cancer and cardiac complications of cancer therapy is an increasing clinical problem. Optimum management of cardiovascular disease can allow patients with cancer to successfully receive cancer therapies and it can reduce morbidity and mortality caused by cardiovascular disease in cancer survivors. The authors of this review discuss management strategies for cardiovascular disease in patients with cancer, focusing on the prevention and treatment of congestive heart failure and myocardial infarction. Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy

Nature Clinical Practice Oncology 5, 655 (2008). doi:10.1038/ncponc1225

Authors: Aarif Y Khakoo & Edward TH Yeh

]]> Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy Aarif Y Khakoo Edward TH Yeh doi:10.1038/ncponc1225 Nature Clinical Practice Oncology 5, 655 (2008) 2008-09-16 Nature Clinical Practice Oncology 2008-09-16 5 11 Review 655 667 Technology Insight: combined external-beam radiation therapy and brachytherapy in the management of prostate cancer http://dx.doi.org/10.1038/ncponc1224 There have been considerable advances in external-beam delivery and brachytherapy techniques for prostate cancer. Combined-modality therapy with external-beam radiotherapy and brachytherapy is an attractive treatment option for a selected group of patients with clinically localized prostate cancer. Hurwitz discusses the indications for use of combination therapy, choice of low-dose-rate versus high-dose-rate brachytherapy boost, and toxicity and quality of life issues. Technology Insight: combined external-beam radiation therapy and brachytherapy in the management of prostate cancer

Nature Clinical Practice Oncology 5, 668 (2008). doi:10.1038/ncponc1224

Author: Mark D Hurwitz

]]> Technology Insight: combined external-beam radiation therapy and brachytherapy in the management of prostate cancer Mark D Hurwitz doi:10.1038/ncponc1224 Nature Clinical Practice Oncology 5, 668 (2008) 2008-09-30 Nature Clinical Practice Oncology 2008-09-30 5 11 Review 668 676 Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization http://dx.doi.org/10.1038/ncponc1227 The treatment options for patients with chemoresistant diffuse large B-cell lymphoma are limited. Fenske et al. describe the case of a 41-year-old man with chemorefractory lymphoma, who was treated with yttrium-90 microsphere embolization of his hepatic tumors. The patient's lymphoma progressed and he died, but there was no evidence of recurrence in the liver. The authors discuss yttrium-90 microsphere embolization for patients who have chemoresistant lymphoma with involvement of the liver. Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization

Nature Clinical Practice Oncology 5, 677 (2008). doi:10.1038/ncponc1227

Authors: Timothy S Fenske, Heather Benjamin, Steven H Kroft, Eric J Hohenwalter & William S Rilling

]]> Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization Timothy S Fenske Heather Benjamin Steven H Kroft Eric J Hohenwalter William S Rilling doi:10.1038/ncponc1227 Nature Clinical Practice Oncology 5, 677 (2008) 2008-09-16 Nature Clinical Practice Oncology 2008-09-16 5 11 Case Study 677 681 “Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects” http://dx.doi.org/10.1038/ncponc1275 “Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects”

Nature Clinical Practice Oncology 5, E1 (2008). doi:10.1038/ncponc1275

Authors: Nicolas Magné & Cyrus Chargari

]]> “Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects” Nicolas Magné Cyrus Chargari doi:10.1038/ncponc1275 Nature Clinical Practice Oncology 5, E1 (2008) Nature Clinical Practice Oncology 5 11 Article Response E1 E1